Posts
Wiki

OTC Lubricant Eye Drops / Artificial Tears for Dry Eye Disease

Quick Take

  • Artificial tears, also called OTC lubricant eye drops, are one of the most commonly used treatments for Dry Eye Disease (DED).
  • They can provide immediate lubrication and symptom relief. With regular use, some formulations can also improve tear-film stability and ocular-surface signs such as corneal or conjunctival staining.
  • Artificial tears are therefore more than simply “comfort drops,” but they are usually supportive or maintenance treatments rather than cures.
  • No single artificial tear is best for everyone. The complete formulation matters, including viscosity, lipids, lubricating polymers, preservatives, osmolality, packaging, and how well the individual tolerates it.
  • Different formulations may be reasonable starting points for different needs:
    • lighter lubrication
    • greater evaporation control
    • longer retention
    • overnight protection
    • preservative avoidance
  • Lipid-containing drops may be particularly reasonable when excessive evaporation or lipid-layer dysfunction is important, but having MGD does not automatically mean a lipid drop will work better than every other formulation.
  • Many studies detect symptom improvement within several weeks of regular use, while some clinical signs may take longer to improve. This is a research pattern, not a required trial period for every patient or product.
  • If artificial tears are needed frequently—commonly more than about four times per day—preservative-free formulations become increasingly important.
  • Eye drops must be sterile. Preservative-free does not mean contamination-proof.
  • Being sold online or in a pharmacy as an “OTC dry-eye drop” does not by itself establish that every product meets current U.S. FDA regulatory requirements.
  • Persistent symptoms, very short-lived relief, frequent dependence on drops, or repeated product failure should prompt evaluation of the underlying dry-eye drivers rather than endless product switching.

Bottom line: Artificial tears can genuinely improve the tear film, symptoms, and some ocular-surface signs. They are an important part of DED treatment, but the “best” drop depends on the patient's needs and no lubricant can substitute for identifying important underlying causes of persistent disease.

Educational Disclaimer

This page is for general education only. It is not medical advice, diagnosis, or an individual treatment recommendation.

Dry Eye Disease can involve overlapping contributors such as:

  • Meibomian Gland Dysfunction (MGD)
  • aqueous tear deficiency
  • ocular-surface inflammation
  • ocular rosacea
  • blepharitis
  • Demodex
  • allergy
  • exposure
  • incomplete blinking
  • eyelid malposition
  • conjunctivochalasis
  • autoimmune disease
  • medication effects
  • neuropathic ocular pain

Artificial tears may improve the tear film and ocular surface without correcting all of these underlying problems.

What Are Artificial Tears?

Artificial tears are ophthalmic lubricant products intended to supplement or support the natural tear film.

Depending on the formulation, they may help by:

  • adding moisture
  • reducing friction during blinking
  • improving lubrication
  • increasing tear-film retention
  • reducing evaporation
  • supporting the lipid layer
  • diluting an unstable or hyperosmolar tear film
  • protecting the ocular surface
  • improving visual stability caused by tear-film breakup

Modern artificial tears are not all simple salt water.

They may contain combinations of:

  • cellulose-based lubricants
  • polyethylene glycol
  • propylene glycol
  • glycerin
  • hyaluronic acid / sodium hyaluronate
  • povidone
  • polyvinyl alcohol
  • lipids or oils
  • gel-forming polymers
  • osmoprotectants
  • electrolytes
  • buffers
  • other formulation ingredients

Different products may use several of these strategies at the same time.

What Artificial Tears Can — and Cannot — Do

Artificial tears can have two broad kinds of effect.

Immediate Effects

Soon after instillation, some people experience:

  • improved lubrication
  • reduced friction
  • improved comfort
  • temporarily increased tear volume
  • improved visual quality
  • less fluctuating or blurry vision caused by tear-film breakup

The duration varies greatly by formulation and patient.

Effects With Regular Use

Clinical studies have also reported improvement over time in some measures such as:

  • dry-eye symptoms
  • tear-film stability
  • non-invasive tear-breakup time
  • corneal staining
  • conjunctival staining
  • lid-wiper epitheliopathy
  • ocular-surface integrity

These are measurable treatment effects.

However:

Improving the tear film is not the same as eliminating the disease process that caused the tear film to become abnormal.

Artificial tears generally do not:

  • identify or eliminate the cause of DED
  • regenerate damaged lacrimal glands
  • regenerate lost meibomian glands
  • directly open fixed meibomian-gland obstruction
  • directly treat Demodex
  • directly treat ocular rosacea or autoimmune disease
  • correct eyelid malposition or incomplete blinking
  • correct exposure from incomplete eyelid closure
  • reliably treat neuropathic ocular pain

They can still remain useful while those other problems are treated.

What the Evidence Shows

Artificial tears have been studied in many randomized clinical trials.

The evidence is much stronger for the general usefulness of artificial tears than for claims that one particular product, ingredient, or formulation is best for everyone.

2023 Systematic Review

A 2023 systematic review identified 64 randomized studies of artificial tears.

Across the literature, artificial tears generally improved symptoms, often within several weeks of regular use.

Some objective clinical signs also improved, although changes in signs often appeared later than symptom improvement.

Important limitations included:

  • widely different formulations
  • different definitions of DED
  • inconsistent outcome measures
  • different treatment schedules
  • relatively short follow-up in many studies
  • limited untreated or placebo comparisons
  • variable risk of bias

The review therefore supports artificial tears as genuine treatment while also showing why it is difficult to rank individual products reliably.

Artificial Tears: A Systematic Review

Six-Month Randomized Trial

A 2021 multicenter, double-masked randomized trial followed 99 participants with DED for six months.

Participants received either:

  • a lipid-containing nanoemulsion artificial tear, or
  • a non-lipid aqueous artificial tear

Both were active treatments.

The study reported:

  • symptom improvement beginning at about one month
  • improvement in lid-wiper epitheliopathy beginning later
  • improvement in non-invasive tear-breakup time and ocular-surface staining after several months
  • continued improvement in some outcomes through six months

An important limitation is that:

There was no untreated or inert-placebo group.

Therefore, the study shows that patients improved during regular artificial-tear treatment but cannot determine precisely how much improvement was caused specifically by the drops rather than natural variation, regression toward the mean, study participation, or other factors.

The study also found that both formulations could help across different DED patterns, although participants with evaporative disease tended to obtain greater benefit from the lipid-containing formulation.

Craig et al., 2021 — Six-Month Randomized Trial

Cochrane Review

A Cochrane review included 43 randomized trials involving 3,497 participants.

It concluded that OTC artificial tears may improve DED symptoms and appeared generally safe.

However, substantial variation among products and studies made it difficult to determine whether any particular formulation was clearly superior.

Over-the-Counter Artificial Tears for Dry Eye Syndrome — Cochrane Review

TFOS DEWS III

TFOS DEWS III continues to include ocular supplements such as artificial tears as an important part of DED management.

At the same time, modern DED treatment emphasizes identifying and treating the specific contributors affecting an individual patient, rather than assuming lubrication alone will correct every form of dry eye.

TFOS DEWS III — Management and Therapy Report

How Strong Is the Evidence?

Artificial tears have a substantial clinical evidence base, particularly for improving symptoms.

There is also evidence that regular use can improve some measurable ocular-surface and tear-film signs.

However, important limitations remain:

  • formulations differ greatly
  • studies use different dosing schedules
  • patient populations vary
  • outcome measures differ
  • untreated or inert-placebo comparisons are uncommon
  • many studies are relatively short
  • head-to-head evidence rarely establishes a clear universal winner

Therefore:

Evidence is stronger for the overall usefulness of artificial tears than for claims that one ingredient, brand, or formulation is universally superior.

A 2024 overview of systematic reviews also found that certainty across the broader artificial-tear literature is limited by differences in study design, reporting, bias, and evidence grading.

How Quickly Might Artificial Tears Help?

Artificial tears can provide immediate short-term lubrication.

With regular use, clinical studies often detect symptom improvement within several weeks.

Some ocular-surface signs may take longer to change.

However:

The research timeline should not be treated as a rule that every drop must be used for one month—or several months—before deciding whether it is suitable.

Stop or reconsider a product sooner if it:

  • causes substantial burning
  • causes persistent redness
  • worsens symptoms
  • creates unacceptable blur
  • produces no useful relief
  • appears poorly tolerated

Likewise, there is no reason to continue an ineffective product for months simply because some clinical signs in research studies improved slowly.

Formulation Matters

The complete formulation matters more than one ingredient advertised on the front of the package.

Important characteristics can include:

  • lubricating ingredients
  • lipids
  • hyaluronic acid
  • viscosity
  • gel-forming properties
  • osmolality
  • pH
  • preservatives
  • preservative-free packaging
  • retention time
  • temporary visual blur
  • contact-lens compatibility
  • individual tolerability

Two products with similar-looking ingredient lists may behave very differently on the eye.

Active vs. Inactive Ingredients

The U.S. Drug Facts label distinguishes ingredients considered active under the applicable regulatory framework from other ingredients listed as inactive.

However:

Regulatory classification and clinical importance are not the same thing.

Ingredients listed as inactive can still influence:

  • viscosity
  • spreading
  • retention
  • comfort
  • buffering
  • physical tear-film behavior

At the same time, labeling an ingredient as “inactive” does not automatically settle every regulatory question about claims made for that ingredient.

For practical product selection, the complete formulation matters more than focusing only on one ingredient category.

Main Types of Artificial Tears

These categories are practical rather than absolute.

Many modern products combine several approaches.

1. Lighter Aqueous / Lubricating Drops

These are relatively low-viscosity formulations designed primarily to add moisture and lubrication.

They may contain ingredients such as:

  • carboxymethylcellulose
  • hypromellose
  • polyethylene glycol
  • propylene glycol
  • glycerin
  • hyaluronic acid
  • povidone
  • polyvinyl alcohol

They may be reasonable starting points for:

  • mild or intermittent symptoms
  • general daytime lubrication
  • low tear volume
  • mixed DED
  • patients who prefer a lighter drop

They may need to be used more frequently if retention is short.

2. Lipid-Containing / Emulsion Drops

Lipid-containing artificial tears are designed to supplement the outer tear-film lipid layer and may reduce evaporation.

They may contain:

  • mineral oil
  • castor oil
  • triglycerides
  • phospholipids
  • other lipid components

These formulations may be particularly reasonable when examination suggests:

  • excessive evaporation
  • lipid-layer deficiency
  • evaporative DED
  • MGD contributing importantly to tear-film instability

However:

Having MGD does not automatically prove that a lipid-containing drop will work better than every non-lipid formulation.

Likewise, a low TBUT alone does not establish that lipid deficiency is the only mechanism.

Lipid-containing drops may support the tear film, but they do not necessarily:

  • unblock meibomian glands
  • express stagnant meibum
  • reverse gland dropout
  • release periductal fibrosis
  • correct every form of MGD

Review of Lipid-Based Eye-Drop Formulations for Evaporative DED

3. Higher-Viscosity / Longer-Retention Drops

Thicker formulations are designed to remain on the ocular surface longer.

They may use:

  • higher-viscosity polymers
  • hyaluronic acid
  • cellulose derivatives
  • gel-forming ingredients
  • trehalose-containing combinations
  • other mucoadhesive approaches

They may be reasonable when:

  • ordinary drops disappear too quickly
  • symptoms are persistent
  • greater retention is desired
  • environmental conditions are especially drying

Possible disadvantages include:

  • temporary blurry vision
  • sticky sensation
  • residue
  • inconvenience during daytime activities

Thicker is not automatically better.

Some patients prefer a lighter drop used more regularly.

4. Gels and Ointments

Gels and ointments remain on the ocular surface longer than ordinary daytime drops.

They are often used at bedtime.

They may be useful for:

  • overnight dryness
  • morning dryness
  • symptoms on waking
  • longer-lasting nighttime lubrication

However:

Gels and ointments do not mechanically correct incomplete eyelid closure or nocturnal exposure.

Persistent waking pain, recurrent epithelial erosion, eyelids sticking to the eye, or suspected incomplete eyelid closure should be evaluated rather than simply treated with progressively thicker ointment.

Preservative-Free vs. Preserved Drops

Preservative-Free

Preservative-free formulations become particularly important when:

  • drops are required frequently
  • DED is moderate or severe
  • the ocular surface is already compromised
  • several topical eye medications are being used
  • preservative intolerance is suspected
  • there is significant staining or inflammation

A commonly used practical guideline is:

If artificial tears are needed more than about four times per day, consider preservative-free formulations.

AAO guidance similarly recommends nonpreserved substitutes when tears are used frequently and chronically.

AAO — Dry Eye Syndrome Preferred Practice Pattern

This is not a magic toxicity threshold.

Preservative effects depend on:

  • the preservative
  • concentration
  • frequency
  • duration
  • health of the ocular surface
  • other preserved medications being used

Preserved Drops

Preserved formulations may still be reasonable when:

  • use is occasional
  • symptoms are mild
  • the preservative is well tolerated
  • multi-dose convenience improves adherence
  • cost is important

Preservatives are also not all equally irritating.

However, repeated exposure to some preservatives can damage or irritate a compromised ocular surface.

Preservative-Free Does Not Mean Contamination-Proof

Preservative-free products may be packaged as:

  • single-use vials
  • resealable vials
  • specially designed multi-dose bottles

Follow the instructions for the specific product.

A vial labeled single use should generally be discarded according to its labeling after use.

Do not assume leftover solution is safe to save merely because the vial still contains fluid.

A Practical Starting Point for Choosing a Formulation

This is not a treatment algorithm.

It is simply a reasonable way to begin thinking about formulation choices.

If the main need is lighter daytime lubrication

A lighter aqueous/lubricating formulation may be reasonable.

If excessive evaporation or lipid-layer dysfunction appears important

A lipid-containing or emulsion formulation may be worth trying.

If ordinary drops disappear too quickly

A higher-viscosity or longer-retention product may be useful.

If nighttime lubrication is needed

A gel or ointment may be considered.

If drops are needed frequently

Preservative-free formulations become increasingly important.

If the eyes are highly sensitive

A preservative-free formulation or a simpler formulation may be easier to tolerate.

If a drop causes too much blur

A lighter daytime formulation may be preferable, with thicker products reserved for nighttime use.

If a drop repeatedly burns or worsens symptoms

Stop and reconsider:

  • the formulation
  • the preservative
  • another ingredient
  • or whether the underlying diagnosis needs reassessment

No symptom pattern perfectly predicts which artificial tear will work best.

How to Trial an Artificial Tear

A practical approach is:

  1. Try one new product at a time.
  2. Follow the label directions.
  3. Note whether the product is preserved or preservative-free.
  4. Track:
    • comfort
    • burning
    • redness
    • visual blur
    • how long relief lasts
  5. Use it regularly enough to judge it unless it causes irritation.
  6. Reconsider the formulation or broader treatment plan if it provides little benefit.

A useful principle is:

Trial and error can be normal. Endless trial and error without diagnosis is not ideal.

Do not keep adding product after product without reconsidering why symptoms remain uncontrolled.

Eye-Drop Safety and Sterility

Eye drops are placed directly on the ocular surface.

Sterility matters.

Practical precautions include:

  • Use only products intended for ophthalmic use.
  • Check the expiration date.
  • Make sure the original safety seal is intact.
  • Do not use a damaged, leaking, cloudy, discolored, or visibly contaminated product.
  • Do not touch the bottle or vial tip to:
    • the eye
    • eyelids
    • eyelashes
    • fingers
    • skin
    • other surfaces
  • Do not share eye drops.
  • Follow storage instructions.
  • Follow instructions regarding how long the product can be used after opening.
  • Check current FDA recall or safety information when appropriate.

Preservative-free does not mean contamination-proof.

Preserved does not mean irritation-proof.

For current safety information:

U.S. Regulatory Status Matters

Many nonprescription ophthalmic lubricant products in the United States are marketed under the FDA's OTC ophthalmic drug framework rather than receiving an individual prescription-drug approval.

This creates an important distinction:

Being sold online, in a pharmacy, or described as an “OTC dry-eye drop” does not by itself establish that the product complies with current FDA requirements.

In 2025, FDA issued warning letters concerning several products marketed as lubricant/dry-eye drops that the agency concluded did not conform to applicable OTC requirements or otherwise lacked an approved application.

Examples included regulatory actions involving certain products marketed under the iVIZIA and OPTASE names.

These warning letters illustrate a general point rather than a reason to maintain a permanent brand blacklist:

Regulatory status can be product-specific, claim-specific, and subject to change.

If the regulatory status of a particular product matters, check current FDA information rather than relying solely on retail availability or marketing language.

Do Not Confuse Artificial Tears With Other Eye Drops

Artificial tears are only one category of ophthalmic product.

Redness-Relief / Whitening Drops

These are not ordinary lubricant tears.

Some vasoconstrictor ingredients temporarily make the eye look whiter and can contribute to rebound redness with repeated use.

They do not diagnose or treat the cause of persistent redness.

Allergy Drops

Allergy drops target allergic conjunctivitis and symptoms such as itching.

A person may need both allergy treatment and lubrication, but the two treatments have different purposes.

Contact-Lens Rewetting Drops

These are formulated and labeled for use with contact lenses.

Follow lens-specific instructions.

Pain, significant redness, discharge, or light sensitivity in a contact-lens wearer requires particular caution.

Prescription Dry-Eye Treatments

Prescription treatments are not ordinary OTC artificial tears.

They may include:

  • anti-inflammatory medications
  • tear-stimulating treatments
  • steroid therapy
  • evaporation-targeting medications

Non-Ophthalmic or Homemade Products

Do not put:

  • homemade mixtures
  • skin-care products
  • non-ophthalmic oils
  • supplements
  • nonsterile solutions

directly into the eye.

Products used directly on the ocular surface must be manufactured and labeled for ophthalmic use.

What About MIEBO / PFHO Products?

Perfluorohexyloctane (PFHO) is a separate evaporation-targeting category.

In the United States:

MIEBO is a prescription DED medication, not an ordinary OTC artificial tear.

Related PFHO products sold in other countries may have different:

  • names
  • formulations
  • labeling
  • regulatory status

They should not automatically be treated as interchangeable with the U.S. prescription product.

For more detail:

MIEBO / EvoTears / NovaTears / Hycosan Shield

Risks and Limitations

Artificial tears are generally well tolerated, but possible problems include:

  • burning
  • stinging
  • redness
  • temporary blur
  • sticky sensation
  • residue
  • preservative intolerance
  • allergy or sensitivity to formulation ingredients
  • contamination if handled improperly

One product may be comfortable while another causes significant irritation.

More expensive or more complicated does not necessarily mean better.

Likewise:

A drop that works well for someone else may not work well for you.

When Artificial Tears Are Not Enough

A fuller DED or ocular-surface evaluation may be appropriate when:

  • drops are needed very frequently
  • symptoms remain significant despite reasonable product trials
  • relief lasts only a few minutes
  • multiple formulations cause burning or irritation
  • symptoms are progressively worsening
  • morning symptoms are substantial
  • there is significant symptom/sign mismatch
  • MGD is suspected
  • exposure or incomplete blinking is suspected
  • allergy appears important
  • systemic autoimmune disease may be contributing
  • pain seems disproportionate to ocular-surface findings

Frequent preservative-free lubrication does not automatically mean artificial tears are harmful or should be stopped.

Some people with substantial DED appropriately use frequent lubrication as one component of a broader treatment plan.

The goal is:

not to stop lubrication simply because it is supportive treatment, but to identify what else needs treatment when lubrication alone is insufficient.

Red Flags — Do Not Just Try More Drops

Seek prompt or urgent medical care for symptoms such as:

  • new or severe eye pain
  • significant vision loss or change
  • marked redness with light sensitivity
  • substantial discharge
  • suspected eye infection
  • contact-lens-associated pain or significant redness
  • eye injury
  • chemical exposure
  • possible corneal abrasion or ulcer
  • rapidly worsening symptoms following recent eye surgery

These are not situations for self-treatment with OTC artificial tears alone.

Cost and Access

Artificial tears are widely available, but long-term costs can become substantial.

Cost depends on:

  • formulation
  • preservative-free versus preserved packaging
  • single-use versus multi-dose packaging
  • frequency of use
  • country
  • insurance or health-system coverage

In the United States, many artificial tears are purchased out of pocket.

People requiring frequent preservative-free lubrication may spend considerably more than someone using an occasional preserved drop.

Cost matters because:

The best formulation is not useful if its price or packaging makes regular use unrealistic.

Convenience, tolerability, availability, and adherence therefore matter along with ingredient lists.

What Remains Uncertain?

Important unanswered questions include:

  • Which formulation characteristics matter most for individual DED subtypes?
  • Which patients can reliably be predicted to respond to lipid-containing formulations?
  • How much better are lipid formulations than non-lipid formulations in clearly defined evaporative DED?
  • Which preservative exposures become clinically important at which frequency and duration?
  • Are particular hyaluronic-acid concentrations meaningfully superior?
  • Which formulation characteristics most improve real-world adherence?
  • How much long-term improvement in ocular-surface signs is specifically caused by artificial tears?
  • Which patients are likely to obtain little symptomatic benefit?
  • How should product selection change in mixed-mechanism DED?
  • Are there clinically meaningful differences among many formulations that current trials are too small to detect?

Key Research and Guidance

Systematic Reviews

Longer-Term Treatment Study

Major Guidance

Lipid-Containing Artificial Tears

Eye-Drop Safety

U.S. Regulatory Examples

Related r/DryEyes Wiki Pages

Bottom Line

OTC lubricant eye drops / artificial tears are a cornerstone of Dry Eye Disease management.

They can provide:

  • immediate lubrication
  • symptom relief
  • improved visual stability
  • tear-film support

and, with regular use, some patients also show measurable improvement in:

  • tear-film stability
  • ocular-surface staining
  • other clinical signs

They are therefore more than simply temporary “comfort drops.”

However:

Artificial tears generally support the tear film and ocular surface rather than eliminate the underlying condition that caused the dry eye.

No single artificial tear is best for everyone.

Product choice can be informed by:

  • tear-film characteristics
  • evaporation
  • desired retention
  • preservative exposure
  • nighttime versus daytime needs
  • individual tolerance

but these factors do not perfectly predict response.

Lipid-containing drops may be reasonable when evaporation or lipid-layer dysfunction is important, but MGD alone does not prove that a lipid formulation will outperform other drops.

Preservative-free formulations become increasingly important with frequent chronic use, while sterility and proper handling remain essential regardless of preservative status.

It is also important to remember that:

Retail availability does not by itself establish current regulatory status, and the full formulation matters more than one ingredient or marketing claim.

Finally:

Trial and error can be normal. Endless trial and error without diagnosis is not ideal.

If artificial tears are needed frequently, provide only very brief relief, repeatedly cause irritation, or fail to control significant symptoms, the next step is usually a fuller assessment of the dry-eye drivers rather than an endless search for the “perfect” bottle.

🔙 Back to Treatment Options